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Abstract: Chloroquine (CQ) and hydroxychloroquine (HCQ) have been proposed as treatments
for COVID-19. These drugs have been studied for many decades, primarily in the context of
their use as antimalarials, where they induce oxidative stress-killing of the malarial parasite.
Less appreciated, however, is evidence showing that CQ/HCQ causes systemic oxidative stress.
In vitro and observational data suggest that CQ/HCQ can be repurposed as potential antiviral
medications. This review focuses on the potential health concerns of CQ/HCQ induced by oxidative
stress, particularly in the hyperinflammatory stage of COVID-19 disease. The pathophysiological
role of oxidative stress in acute respiratory distress syndrome (ARDS) has been well-documented.
Additional oxidative stress caused by CQ/HCQ during ARDS could be problematic. In vitro data
showing that CQ forms a complex with free-heme that promotes lipid peroxidation of phospholipid
bilayers are also relevant to COVID-19. Free-heme induced oxidative stress is implicated as a systemic
activator of coagulation, which is increasingly recognized as a contributor to COVID-19 morbidity.
This review will also provide a brief overview of CQ/HCQ pharmacology with an emphasis on how
these drugs alter proton fluxes in subcellular organelles. CQ/HCQ-induced alterations in proton
fluxes influence the type and chemical reactivity of reactive oxygen species (ROS).
Keywords: oxidative stress; COVID-19; chloroquine; hydroxychloroquine; reactive oxygen species;
proton fluxes; SARS-CoV-2

1. Introduction
At the writing of this review (mid-2020), there was no Food and Drug Administration (FDA)
approved drugs for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA virus infection,
which causes the coronavirus disease 2019 (COVID-19). Both chloroquine (CQ) and hydroxychloroquine
(HCQ) are 4-aminoquinoline drugs with similar structures, as shown in Figure 1. CQ and HCQ have been
proposed as potential COVID-19 medical countermeasures [1–6]. The FDA currently approves CQ/HCQ
for use as antimalarials, the treatment of rheumatoid arthritis, and systemic lupus erythematosus
(SLE) where they act by immunomodulatory mechanisms [7]. HCQ reduces disease activity in SLE
patients but has no significant effect on pro-inflammatory cytokines [8]. A recent literature review
highlights many immunomodulatory mechanisms influenced by CQ/HCQ and emphasizes our lack of
current knowledge concerning their potential effects on immune responses in COVID-19 patients [9].
CQ/HCQ use may lead to unknown alterations in immune responses in COVID-19 patients, including
diminished innate immune responses as well as potential modifications of the B and T cell responses
to the COVID-19 virus [9].
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Figure 1. The organic structures of (a) hydroxychloroquine (HCQ); (b) chloroquine and; (c) heme.
Chloroquine can form a membrane bound complex with heme that can promote lipid peroxidation
(see Figure
and text).
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of oxidative stress in COVID-19 is critical, since potential anti-COVID-19 drug candidates that
increase oxidative stress have the potential to exacerbate ARDS pathophysiology.
2. CQ/HCQ Pharmacology and Alterations in Subcellular Organelles Proton Fluxes
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Before reviewing the role of CQ/HCQ in redox physiology and SARS-CoV-2 infection, we will
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Figure 2. Chloroquine (CQ) and hydroxychloroquine (HCQ) are cationic amphiphilic drugs (CADs)
that share a set of common pharmacological properties: (a) they can partition into biomembranes;
(b) accumulate in the lumens of acidic subcellular organelles, and; (c) induce a generalized
phospholipidosis, which is the lysosomal accumulation of phospholipids.
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The binding of CADs to lipid bilayers is stabilized by nonspecific hydrophobic and ionic
interactions [31]. Lipid bilayers are present in all cells and many subcellular organelles. It follows
that CADs can accumulate, to some extent, in the cells and membranous organelles of most tissues.
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CAD accumulation can potentially affect many functions of all biological membranes by altering their
structure and functions, e.g., membrane-bound lysosomal phosphatases and hydrolases [33].
4. CQ/HCQ Accumulate in the Lumens of Acidic Subcellular Vesicles and Alter Proton Fluxes
It is also well established that CADs accumulate in the lumens of acidic subcellular vesicles.
The neutral forms of CADs can freely diffuse through the hydrophobic domain of lipid bilayers.
For acidified vesicles, such as endosomes, lysosomes, M2 phagosomes, and pulmonary lysosomal
lamellar bodies, the neutral forms of CADs will become charged inside the lumen and will no
longer be able to diffuse out [28]. Acidified vesicles utilize a vacuolar proton-pumping ATPase
(V-ATPase) to maintain a low pH by pumping protons across the vesicular membrane into the
lumen [34]. For lysosomes attempting to maintain a low pH (pH 4.8) in the presence of CQ/HCQ,
there will be a gradual luminal accumulation of CQ/HCQ, eventually leveling off at levels as high
as 20 mM [28,35]. This process is termed “lysosomal trapping,” and trapped CADs are denoted as
“lysosomotropic” [35–37]. CQ shows a wide variation in lysosomal trapping between organs with
lungs > kidney = brain = liver > diaphragm = heart = skeletal muscles > adipose tissue [38]. The high
CQ accumulation in the lungs is relevant to respiratory distress disorders [39].
Lamellar bodies are a type of acidified lysosome found in type II alveolar cells (T2ACs),
and keratinocytes and these organelles are known to accumulate weak bases such as CQ/HCQ [40,41].
The lamellar bodies found in T2ACs secrete surfactant, which is essential for pulmonary alveoli
gas exchange [42]. T2ACs are particularly relevant to COVID-19, since these cells express
angiotensin-converting enzyme-2 (ACE-2), which SARS-CoV-2 utilizes as a receptor to enter the lungs.
T2AC cells are preferentially infected by SARS-CoV-2, potentially contributing to a reduced secretion
or function of surfactant with a resulting loss of pulmonary compliance [43]. Reduced pulmonary
compliance is a typical characteristic of ARDS, but exogenous surfactant treatment has not proven to
be therapeutically effective [44,45]. Nevertheless, there is a pharmaceutical interest in testing surfactant
therapy in COVID-19 patients. CQ interferes with the processing of surfactant protein C, which is
necessary for a fully functional surfactant [46]. Moreover, ROS can inactivate surfactant by structural
and functional modifications to surfactant proteins SP-B and SP-C [47].
Initial in vitro data suggested that the pH of lysosomes would increase as a result of CAD trapping,
but subsequent, more detailed studies do not support this view [30,35,48,49]. Data in an animal model
show, for example, that CQ (40 mg/kg body weight) will transiently increase hepatocyte lysosomal pH
from 4.8 to 6.8 for about 2 h, followed by a return to pH 4.8 lasting for at least 10 h [49]. Maintaining an
acidic lysosomal pH in the face of CQ accumulation necessitates an increased ATP consumption by
V-ATPase and an increased proton flux into the lysosomal lumen.
5. Endosomal-Lysosomal Proton Fluxes, CQ/HCQ and SARS-CoV-2
A third well-studied effect caused by CADS (see Figure 2) is a generalized lysosomal accumulation
of phospholipids termed phospholipidosis. Phospholipidosis is a lysosomal storage disorder
characterized by an abnormal accumulation of phospholipids in the form of lamellar bodies [30].
Drugs causing phospholipidosis are recognized as being potentially toxic by the pharmaceutical
industry [50,51]. The underlying mechanism(s) for phospholipidosis remains a matter of some
controversy. Most likely, CAD inhibition of lysosomal lipid degradation enzymes is involved [30].
Studies in an animal model indicate that CADs can induce pulmonary lesions characterized by large
foamy macrophages in the alveolar spaces [51]. The foamy alveolar macrophages show a typical
CAD-induced lysosomal phospholipidosis with the potential to interfere with the phagocytosis
and catabolism of pulmonary surfactant [51]. The potential pathophysiological consequences of
phospholipidosis remain an area of active interest.
The view that lysosomes are relatively inert organelles with a narrow degradative function is
rapidly changing [36]. We now appreciate that lysosomes are dynamic organelles playing a central role
in a wide variety of signaling pathways affecting immune responses, viral infectivity, the inactivation
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of microbes, and inflammation [35,52,53]. Alterations in luminal proton fluxes can be induced by
both CQ/HCQ and ROS (see below). Proton fluxes can, in turn, influence both the levels and types of
ROS [54].
Lysosomes can fuse with endosomes, thereby delivering the endocytosed cargo to lysosomes [55].
Pioneering work by Burkard et al. shows that coronavirus entry into cells can occur via this
endolysosomal (or endocytic) pathway [56]. The endolysosomal pathway is under intense scrutiny
due to its role as a target for COVID-19 therapy [57]. The spike glycoprotein (S) of SARS-CoV-2 is
proteolytically cleaved by cellular serine protease TMPRSS2 into two subunits, S1 and S2 [58]. The S1
viral protein binds to the host cell angiotensin-converting enzyme 2 (ACE2) plasma membrane protein.
The SARS-CoV-2 interaction with ACE2 initiates the formation of clathrin-coated pits, which serve
as SARS-CoV-2 entry receptors. The virus is then brought into the cell’s cytoplasm via endocytosis
with the formation of early endosomes. The early endosomes with SARS-CoV-2 subsequently form
late endosomes that fuse with lysosomes. The S2 protein subunit promotes the fusion of the viral
membrane with cellular membranes [57–59]. Encouragingly, sera from recovered SARS patients can
block SARS-CoV-2 host cell entry in a cell culture model [58].
The notion that CQ/HCQ could alkalinize endosomal-lysosomal pH and thereby inhibit the
replication of viruses requiring an acidic pH has been an attractive hypothesis [60]. This potential
mechanism is often proposed as a rationale for the CQ/HCQ treatment of COVID-19 [61]. Nevertheless,
the references cited above cast doubt on this hypothesis, since CQ/HCQ endosomal-lysosomal
alkalinization appears to be only transient, lasting only a few hours, but long enough to confound
short-term in vitro experiments.
As mentioned above, CQ/HCQ are likely to increase cellular ATP consumption and increase
proton flux across the lysosomal membrane. Under conditions where ATP production is decreased (e.g.,
mitochondrial uncoupling or hypoxia) sufficiently to inhibit V-ATPase activity, it might be possible for
CQ/HCQ to induce some degree of endosomal-lysosomal alkalinization [62]. Low V-ATPase protein
expression could also cause CQ/HCQ alkalinization. This avenue of research is not well studied.
Intracellular ATP levels are also a key determinant governing the mode of cell death: lack of ATP favors
necrosis over apoptosis [63]. Although beyond the scope of this review, it should be noted that many
viruses have evolved molecular mechanisms to modulate modes of cell death to their advantage [64].
Blocking apoptosis and the subsequent killing of virally infected cells is one such mechanism [64].
6. Redox Physiology, Reactive Oxygen Species (ROS) and Oxidative Stress
We will next provide a brief overview of redox physiology and its interconnections to proton
fluxes and CQ/HCQ. Redox physiology is an inclusive term referring to the complex role that
oxidation-reduction reactions play in both normal and pathophysiological processes, including the
role of ROS in modulating signal transduction pathways (e.g., NF-kappaB transcription factor) and
inflammatory responses [65]. ROS is a term used to describe small oxygen-containing molecules that
are reactive or give rise to reactive species. The name “reactive oxygen species” is preferable to “free
radical species”, since not all free radical oxygen species are very reactive, and some non-free radical
oxygen species are very reactive, e.g., singlet oxygen. Moreover, hydrogen peroxide is considered a
primary ROS and is not a free radical. The primary ROS are superoxide (O2 •− where • is an unpaired
electron), hydrogen peroxide (H2 O2 ), and the hydroxyl radical (•OH) [66]. Secondary ROS, such as
hypochlorous acid (HOCl) and lipid peroxyl radicals (LOO•), can be derived from primary ROS (see
below). Oxidative stress is a redox imbalance occurring when the production of ROS and/or reactive
nitrogen oxide species (RNOS) is sufficient to cause physiological damage [67]. An overproduction of
ROS/RNOS and/or deficient levels of antioxidants (e.g., glutathione) can result in oxidative stress.
7. Mitochondria, ROS, Hypoxia, and CQ/HCQ
As indicated in Figure 3, the mitochondrial respiratory chain electron transport chain (ETC)
is a major source of ROS for most cells undergoing normal metabolism, e.g., noninflammatory
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factor NF-kappaB by ROS can induce the expression of pro-inflammatory cytokines and chemokines.
•− is present as an anion but, at low pH, is protonated to form the hydroperoxyl
At pH 7.4,
2
NF-kappaB activation
alsoOpromotes
the expression of key antioxidant enzymes such as SOD2, SOD1,
• ), as indicated in reaction 3. HO • is much more reactive oxygen species than O •− .
radical
(HO
2
2
2
HO-1, and GPX [72]. In vitro experiments have demonstrated
that CQ is capable of evoking NFSince HO2 • is not charged, it can enter lipid bilayers and initiate lipid peroxidation of biological
membranes [78]. As discussed below, the pH of an acidified phagosome is typically 4.5, and most
of the O2 •− would be present as HO2 • . Since CQ/HCQ can alter proton fluxes in many subcellular
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organelles, these drugs can change the type of ROS present and the ability of ROS to damage cells and
subcellular organelles.
Mitochondria contain a superoxide dismutase (SOD) enzyme with a manganese cofactor (MnSOD
or SOD2) which can reduce O2 •− to H2 O2, as indicated in reaction 4. The H2 O2 produced in the
mitochondrial matrix can be reduced by selenocysteine-containing glutathione peroxidase (GPX1),
which utilizes reduced glutathione (gamma-L-glutamyl-L-cysteinyl glycine or GSH) (see reaction 5).
GSH is the major intracellular chemical antioxidant. GPX1 is found in the cytoplasm and mitochondria.
As detailed below, CQ induces a systemic decrease in GSH levels. GPX1 can modulate mitochondrial
functions that, in turn, can regulate many redox-dependent cellular responses [79]. H2 O2 produced in
the mitochondrial matrix can diffuse through the inner and outer mitochondrial membranes to the
cytoplasm (see Figure 3).
H2 O2 , in the presence of ferrous ions, can be reduced to the highly reactive hydroxyl radical (•OH)
which can abstract a hydrogen from a polyunsaturated fatty acid (PUFA) moiety (LH) to form a lipid
hydroperoxide (LOOH), as shown in Reactions 6-8. As detailed more below, ferritin functions as an
antioxidant protein by preventing redox-active iron ions from generating ROS. The various forms of
vitamin E (mostly RRR-alpha-tocopherol and RRR-gamma-tocopherol) can quench the free radicals
produced during lipid peroxidation. If not quenched, the LOO• from Reaction 9 can start another cycle
of lipid peroxidation (Reactions 7 and 8) since the LH moieties in biomembranes are in close and fluid
contact. Vitamin E (TOH) is the major lipid-soluble antioxidant and is present in all biomembranes.
GPX

H2 O2 + 2GSH −−−→ 2H2 O + GSSG

(5)

H2 O2 + Fe2+ → OH− + • OH + Fe3+

(6)

LH + • OH → L• + H2 O

(7)

L• + O2 → LOO•

(8)

LOO• + LH → LOOH + L•

(9)

LOO• + TOH → LOOH + TO•

(10)

Only limited data exist on how CQ/HCQ affects mitochondria ROS production or mitochondrial
functions in general. As mentioned above, both CQ and HCQ (see Figure 1) are CADs, and the
biochemistry of this group of compounds has been intensively studied [31]. Since CADs are positively
charged, they can accumulate in the negatively charged mitochondrial matrix, where they could alter
proton fluxes, ROS production, and potentially disrupt mitochondrial functions [75].
Although there are minimal data on the potential accumulation of CQ/HCQ in mitochondria,
there is clear evidence suggesting that CQ/HCQ affect mitochondrial functions. Early work with
rat liver mitochondria shows that CQ alters mitochondrial lipid composition, decreases the
activities of NADH dehydrogenase, succinate dehydrogenase, and cytochrome c, and inhibits both
mitochondrial respiration and ATP synthesis [80]. Subsequent work confirms that CQ adversely
affects rat liver mitochondria by markedly decreasing respiration rates and by acting as an uncoupler.
Uncoupling occurs when energy is expended by creating a proton gradient (or protonmotive force) but
not utilized in making ATP [81]. In the above-cited work, CQ was administered to rats for extended
periods (7 days, 14 days) before isolating mitochondria and characterizing functional alterations. Since
CQ is transformed into excretable metabolites by microsomal cytochromes, these metabolites may
cause or contribute to the observed mitochondrial changes. In any event, mitochondrial uncoupling is
closely linked to ROS production [82]. Moreover, the isolated mitochondria may have been the target
of oxidative stress generated elsewhere in the cell rather than the source of oxidative damage.
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8. Phagocytes, Proton Flux, ROS and CQ/HCQ
Both neutrophils and macrophages play critical roles in the innate immune response by direct
respiratory burst ROS-mediated virus killing and by the phagocytosis of apoptotic virus-infected
cells [83,84]. These cell types are also consequential in ARDS pathology, which accounts for many of the
deaths associated with COVID-19 [23,24]. Phagocytic cells are also central to the cytokine storm, which
is considered “the most dangerous and potentially life-threatening event related to COVID-19” [85].
The ROS produced by phagocytic cells can also damage vascular endothelial cells, which is increasingly
recognized as significant in the adverse cardiovascular effects of COVID-19 [86–88].
The large amount of O2 *− produced during the “respiratory burst” is accomplished by the transfer
of an electron (e−) from nicotinamide adenine dinucleotide phosphate (NADPH) to oxygen (see
Reaction 11), as catalyzed by NADPH oxidase (NOX2) [89,90].
NOX2

2O2 + NADPH −−−−−→ 2O2 •− + NADP+ + H+

(11)

The O2 •− produced during the respiratory burst of phagocytic cells is secreted into the phagosomes
that have engulfed pathogens [91,92]. The ROS that kills viral and bacterial pathogens is primarily
hypochlorous acid (HOCl) produced by myeloperoxidase (MPO), as shown in Reaction 12.
MPO

H2 O2 + Cl− −−−−→ HOCl

(12)

CQ is a potent in vitro inhibitor of MPO, suggesting that it could compromise the neutrophil
killing of microbes [93]. In vitro studies of human polymorphonuclear neutrophils (PMNs) also show
that CQ induces dysfunction in chemotaxis, phagocytosis, and respiratory burst [94]. Whether or not
these in vitro studies have physiological significance is not clear.
The luminal pH of phagosomes can influence their ability to inactivate microbes [14,52,53].
CQ/HCQ can modulate the pH of phagosomes and thereby modulate the immune responses of
macrophages [95]. The O2 •− generated by reaction 11 occurs in the phagosomal lumen, but the H+
generated is released to the cytoplasm [53]. Moreover, the subsequent dismutation of O2 •− (reaction 4)
in the phagosomal lumen will consume H+ . In the absence of V-ATPase, these events would promote
cytosol acidification and phagosome alkalization. The very high levels of O2 •− produced during the
respiratory burst produces major alterations in the proton fluxes in both the macrophage cytosol and
phagosomes [53].
Macrophages have phenotypic plasticity called “macrophage polarization,” which enables them
to modulate their immunological responses to pathogens and tissue damage. M1 and M2 macrophages
represent two extremes of this phenotypic plasticity. M1 macrophages are optimized to kill pathogens,
and M2 macrophages are optimized for tissue healing [96]. Proton fluxes in the phagosomes of M1
and M2 are different and differentially modulated by CQ/HCQ. M2 macrophages have a very active
V-ATPase and, therefore, can maintain an acidified phagosome after initiation of a respiratory burst [14].
A low phagosomal pH is essential for maintaining the activity of lytic enzymes needed for the
degradation of apoptotic cells (as well as virally infected apoptotic cells). In contrast, M1 macrophages
have phagosomes with much less V-ATPase and hence will not acidify after the initiation of a respiratory
burst [14].
In vitro data indicate that M1 macrophages can generate higher levels of NOX2-generated ROS than
M2 macrophages, suggesting that M1 macrophages would be superior to M2 macrophages at killing
phagocytized viral pathogens [14]. In contrast, M2 macrophages would be more efficient at digesting
dying cells than M1 macrophages, since an acidic pH is optimal for the lytic activity of many phagosomal
digesting enzymes [14]. M2 macrophages would be critical for the removal of virally infected apoptotic
or necrotic host cells and antigen presentation. Moreover, the phagocytic removal of dying host cells is
vital for resolving the inflammation associated with infection and for restoring damaged tissue [97].
M1 macrophages are considered pro-inflammatory and promote tissue damage [95]. In vitro studies
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by Chen et al. [95] show CQ can “reset” macrophages towards the M1 phenotype due to CQ-induced
alkalization of the phagosomal lumen. If this CQ-induced M1-macrophage reset occurred in vivo,
it would not bode well for late-stage CQ/HCQ COVID-19 treatment.
Labro et al. studied the in vitro effects of CQ on human polymorphonuclear neutrophil (PMNs) [94].
CQ at 100 µg/mL (but not lower) inhibited both phagocytosis (50%) and the respiratory burst (80%).
The CQ concentrations used in these experiments are much higher than typically obtained by oral
CQ administration, where a 600 mg dose results in a peak plasma CQ concentration of about
0.3–0.4 µg/mL [94].
9. Evidence for Oxidative Stress Induced by CQ/HCQ
We will next review both the in vitro and in vivo evidence for CQ/HCQ-induced oxidative stress.
This research is relevant to COVID-19, since accumulating evidence suggests that oxidative stress is
linked to the pathology of SARS-CoVs infections [98]. Additional oxidative stress induced by CQ/HCQ
could exasperate viral-induced ARDS pathology.
The historical impetus for studying the relationship between CQ/HCQ and oxidative stress
relationship springs from the widely held hypothesis that CQ exerts its antimalarial effect by oxidative
stress-killing of Plasmodium falciparum parasites during the intra-RBC phase of their life cycle [21,99].
Moreover, high doses of CQ are associated with oxidative stress-induced retinopathy [100,101].
10. CQ/HCQ Influence on Oxidative Stress In Vivo and Ex Vivo
There are very few clinical studies looking at the connections between CQ/HCQ treatment and
oxidative stress. Farombi et al. measured oxidative stress parameters in subjects being treated with CQ
for malaria (Plasmodium falciparum) [19]. Four groups were studied (n = 10 per group): (1) a CQ-treated
group with malaria; (2) a CQ-treated group without malaria; (3) a control group not treated and
without malaria; (4) a second control group not treated with CQ but having malaria. CQ was provided
for three days at a dose of 25 mg/kg body weight. The CQ-treated groups had significantly lower
RBC levels of catalase (CAT) and GPX activities compared with the nontreated groups, while SOD1
increased. SOD1 is a copper/zinc form of SOD. The increased RBC SOD1 activity was viewed as an
adaptive response to oxidative stress, which is a typical result of such stress. Plasma levels of vitamin
A, C, GSH, and beta-carotene (all chemical antioxidants) were significantly decreased by CQ treatment,
while malondialdehyde (MDA) levels (a measure of lipid peroxidation) were increased. Low GSH
is typically the result of increased GSH consumption by GPX (reaction 5). Vitamin E levels were not
measured. Farombi et al. concluded that CQ-treatment-induced systemic oxidative stress in human
subjects [19].
Animal models also support the role of CQ treatment in inducing systemic oxidative stress.
Ogunbayo [102] examined oxidative stress parameters in the whole blood and serum from rabbits after
a single dose (10 mg/kg body weight) of CQ phosphate. Serum GSH levels were found to significantly
decrease 6 and 12 h after CQ administration and return to baseline after 24 h. MDA levels were
significantly increased 6 h after CQ administration. A decreased GSH serum level and an increased
serum MDA level is good evidence for systemic CQ-induced oxidative stress. The RBC activity of
two key antioxidant enzymes was also measured in this study. RBC SOD1 significantly increased 6 h
after oral CQ administration followed by a return to baseline after 24 h. The increase in SOD1 after 6 h
of CQ administration was interpreted as a protective response to increased RBC production of O2 •− .
RBC CAT levels were found to be significantly decreased at 6 h. CAT converts H2 O2 to H2 O, and
O2 *− inactivates its activity. The activity of GPX was not measured in this study, nor were antioxidant
enzyme protein levels accessed by Western blots.
A more extensive study examined the effects of long-term CQ and primaquine (PQ) administration
on oxidative stress parameters in a rat model [103]. CQ increased kidney MDA levels after 7 and
14 days of CQ administration but not at 21 days. CQ did not alter liver levels of MDA at any time
point. Protein carbonyl levels in the kidney were increased by CQ on day 14 but not on day 7 or 21.
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DNA damage was evaluated using the comet assay, which is considered an indirect measure of DNA
strand breaks caused by systemic oxidative stress [104]. DNA damage was markedly increased in the
kidney by CQ on day 7 and 14 but not at day 21. Both the brain and liver showed marked increases in
CQ induced DNA damage at days 14 and 21.
Bhattacharyya et al. [100] looked at the effects of CQ on NADPH-induced lipid peroxidation,
antioxidant enzymes, and the GSH content of the rat retina after both acute and chronic CQ
administration. The retina is particularly sensitive to oxidative stress damage since it has the
highest polyunsaturated fatty acid (PUFA) content of any tissue as well as the highest oxygen
consumption [105]. A high PUFA content in a tissue markedly increases its susceptible to lipid
peroxidation [106]. Bhattacharyya et al. [100] found that acute CQ (0.5 and 4 h after intraperitoneal
injection) increased NADPH-induced lipid peroxidation and decreased retinal tissue GSH content.
In marked contrast, chronic CQ did not induce NADPH-induced lipid peroxidation and increased
the retinal GSH content. SOD and GPX activity decreased after both acute and daily CQ while SOD
increased only in the high-dose acute study.
While the clinical and animal model evidence reviewed above suggests that CQ can induce
systemic oxidative stress, this does not preclude the possibility that CQ/HCQ could simultaneously
exert a localized anti-oxidative role. Similarly, the data for CQ-induced systemic oxidative stress do
not exclude the possibility of very intense but localized oxidative stress. In an ex vivo experiment,
Jancinova et al. found that HCQ (40 mg/kg daily for 21 days) markedly reduced phorbol 12-myristate
13-acetate (PMA)-stimulated oxidant formation in the blood of rats with adjuvant arthritis [107].
Human neutrophils were also examined, and HCQ was found to decrease PMA-stimulated extracellular
neutrophil oxidants but to increase intracellular oxidant formation. The physiological significance of
these results to CQ/HCQ treatment of COVID-19 is not clear but suggests that under some circumstances,
HCQ can act to prevent ROS- induced inflammation.
11. CQ/HCQ Oxidative Stress In Vitro and the Role of Free-Heme
Although very limited, a few in vitro studies on the molecular mechanism(s) of CQ/HCQ induced
oxidative stress are very relevant to COVID-19. In general, bacterial or viral sepsis and ARDS are
often accompanied by the release of heme (iron-protoporphyrin I×) from RBCs and hemeproteins [108].
Heme (see Figures 1 and 4) is very hydrophobic and intercalates in biomembranes, bringing redox-active
iron ions in close contact with the unsaturated fatty acids of membrane phospholipids, thereby
promoting lipid peroxidation [109]. Heme, in an in vitro model system forms a complex with CQ that
induces membrane lipid peroxidation about five-fold higher than observed with heme alone [99,110].
Phospholipids with docosahexaenoic acid (22:6n3) were found to be particularly susceptible to
the heme-CQ induced lipid peroxidation. All-racemic alpha-tocopherol, a synthetic form of vitamin E,
was found to inhibit this heme-CQ-induced lipid peroxidation [99].
The retina has the highest concentration of 22:6n3, thereby contributing to the high sensitivity
of the retina to oxidative stress damage [105]. The retina could, therefore, be particularly susceptible
to oxidative stress damage in CQ/HCQ-treated COVID-19 patients with excess free-heme and low
vitamin E levels. Heme is synthesized in mitochondria, and dysfunctional heme metabolism can
result in mitochondrial oxidative stress [111]. In vitro experiments show that free-heme can cause
mitochondrial dysfunction by reactive lipid species arising from heme-induced lipid peroxidation
(see Figure 4). CQ/HCQ might amplify heme-induced lipid peroxidation damage to mitochondrial
membranes, but this has not been investigated.
Considerable data support the view that heme, even in the absence of CQ, can promote lipid
peroxidation and contribute to inflammation, cytokine production, and vascular injury [112,113].
Sparkenbaugh et al. [114] found that heme induces a systemic activation of coagulation in a mouse model.
Coagulation disorders are increasingly recognized as contributors to severe COVID-19 pathology,
as evidenced by increased levels of D-dimer and fibrin/fibrinogen-degradation products [115,116].
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The potential use of zinc combined with HCQ has received considerable attention as a possible
limitations. The A2780 cells were incubated with CQ for 1 h, during which some CQ could have
treatment for COVID-19, primarily based on data from a few in vitro model systems [120]. One study
converted to metabolites that might function as a zinc ionophore(s).
found that Zn2+, in combination with a zinc ionophore, inhibits the RNA-dependent RNA polymerase
Moreover, CQ could have induced the formation of membrane-bound lipid peroxidation products
with the ability to compromise the impermeability of the A2780 cells’ biomembranes to cations [123].
Alternatively, CQ could have altered the functioning of membrane proteins to promote Zn2+ membrane
permeability. There is nothing chemically obvious about the organic structure of CQ suggesting a
similarity to other Zn ionophores: if anything, CQ, as a cation, should repel metal ion cations. To prove
that CQ is a Zn ionophore would require kinetic studies in a metabolically inert model system such as
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liposomes. Work by Dabbagh-Bazarbachi [124] et al. used this approach to establish that quercetin
functions as a true Zn ionophore. If zinc combined with CQ/HCQ can clinically prevent replication
of SARS-CoV-2 by inhibition of RNA-dependent RNA polymerase, such treatment would likely be
most useful prophylactically or in the early phase of rapid viral replication and less useful in the late
“cytokine storm”, where host-damaging inflammatory responses give rise to severe pathophysiology.
A randomized, open-label trial to assess the safety and efficacy of HCQ and Zn is now underway [125].
13. Conclusions
In an era when precision medicine is an ever-achievable goal, the CQ/HCQ antimalarial drugs
are characterized by nonspecifically influencing many fundamental and diverse cellular structures
and processes, e.g., biomembrane structure and functions, mitochondrial respiration, proton fluxes,
and ROS production. The potential adverse effects of CQ/HCQ on COVID-19 patients, discussed in this
review, are summarized in Figure 5. The literature reviewed here supports the overall view that CQ/HQ
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treatment during the hyperinflammatory phase of COVID-19 could be particularly counterproductive.
In addition to affecting macrophages, as indicted in Figure 5, it is likely that CQ/HCQ indirectly
influence T-cell-mediated immune response by modulating the production of ROS. ROS are known to
play a direct role in modulating T-cell proliferation, differentiation, and T-cell apoptosis [126].
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that CQ did not inhibit SARS-CoV-2 infection of a human lung cell line (Calu-3) [128]. Human lung
cells are a much more relevant cell line than African green monkey kidney cells. To date, two
randomized, double-blind placebo-controlled trials testing the therapeutic potential of HCQ for
COVID-19 have been reported [129,130]. HCQ was not effective in either of these trials. The clinical
trial by Skipper et al. was targeted at early COVID-19 disease and also found (post hoc analysis) that
self-reported use of zinc and vitamin C, along with HCQ, did not improve symptoms [129].

Antioxidants 2020, 9, 894

13 of 19

al. was targeted at early COVID-19 disease and also found (post hoc analysis) that self-reported use of
zinc and vitamin C, along with HCQ, did not improve symptoms [129]. Moreover, adverse effects
occurred more often (p < 0.001) in participants receiving HCQ compared to placebo [129]. A third
multicenter, randomized, open-label trial found that HCQ with or without azithromycin was also not
effective [131].
The potential role of ROS in COVID-19 remains to be fully elucidated. In the case of influenza
A viruses, inhibition of ROS production can reduce inflammation, as measured by a decrease in
virally induced cytokine production [15]. The measurement of oxidative stress parameters in CQ/HCQ
COVID-19 trials would be of clinical value. Quantification of plasma F2-isoprostanes, specifically
8-epi-prostaglandin F2α, is a clinically useful and sensitive assay for assessing in vivo lipid peroxidation
and oxidative stress [132]. Similarly, the plasma ratio of α-tocopherol quinine to α-tocopherol is an
excellent indicator of antioxidant status [132]. Marcello et al. recently found that two oxysterols,
7-ketocholesterol and 7-beta-hydroxycholesterol, were increased in the serum COVID-19 patients,
particularly those with severe signs. These two oxysterols are also useful biomarkers for in vivo lipid
peroxidation [133].
Author Contributions: C.B.K. and W.L.S. contributed equally to this review article. W.L.S. prepared the initial
draft. All authors have read and agreed to the published version of the manuscript.
Funding: This research was supported in part by the National Institutes of Health grant C06RR0306551, a Research
Development Grant (to W.L.S.) from East Tennessee State University, and the East Tennessee State University
Robert W. Summers Pediatric Research Endowment.
Conflicts of Interest: The authors declare no conflict of interest.

References
1.

2.

3.
4.
5.
6.

7.
8.

9.

10.

Duan, Y.J.; Liu, Q.; Zhao, S.Q.; Huang, F.; Ren, L.; Liu, L.; Zhou, Y.W. The Trial of Chloroquine in the Treatment
of Corona Virus Disease 2019 (COVID-19) and Its Research Progress in Forensic Toxicology. Fa Yi Xue Za Zhi
2020, 36. [CrossRef]
Gautret, P.; Lagier, J.C.; Parola, P.; Hoang, V.T.; Meddeb, L.; Mailhe, M.; Doudier, B.; Courjon, J.;
Giordanengo, V.; Vieira, V.E.; et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19:
Results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents 2020, 105949. [CrossRef]
Zhou, D.; Dai, S.M.; Tong, Q. COVID-19: A recommendation to examine the effect of hydroxychloroquine in
preventing infection and progression. J. Antimicrob. Chemother. 2020. [CrossRef]
Cortegiani, A.; Ingoglia, G.; Ippolito, M.; Giarratano, A.; Einav, S. A systematic review on the efficacy and
safety of chloroquine for the treatment of COVID-19. J. Crit. Care 2020. [CrossRef]
Yazdany, J.; Kim, A.H.J. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic:
What Every Clinician Should Know. Ann. Intern. Med. 2020. [CrossRef]
Liu, J.; Cao, R.; Xu, M.; Wang, X.; Zhang, H.; Hu, H.; Li, Y.; Hu, Z.; Zhong, W.; Wang, M. Hydroxychloroquine,
a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov.
2020, 6, 16. [CrossRef]
Shippey, E.A.; Wagler, V.D.; Collamer, A.N. Hydroxychloroquine: An old drug with new relevance.
Cleve Clin. J. Med. 2018, 85, 459–467. [CrossRef] [PubMed]
Willis, R.; Seif, A.M.; McGwin, G.; Martinez-Martinez, L.A.; González, E.B.; Dang, N.; Papalardo, E.;
Liu, J.; Vilá, L.M.; Reveille, J.D.; et al. Effect of hydroxychloroquine treatment on pro-inflammatory
cytokines and disease activity in SLE patients: Data from LUMINA (LXXV), a multiethnic US cohort.
Lupus 2012, 21, 830–835. [CrossRef] [PubMed]
Meyerowitz, E.A.; Vannier, A.G.L.; Friesen, M.G.N.; Schoenfeld, S.; Gelfand, J.A.; Callahan, M.V.; Kim, A.Y.;
Reeves, P.M.; Poznansky, M.C. Rethinking the role of hydroxychloroquine in the treatment of COVID-19.
FASEB J. 2020, 34, 6027–6037. [CrossRef]
Keyaerts, E.; Li, S.; Vijgen, L.; Rysman, E.; Verbeeck, J.; Van Ranst, M.; Maes, P. Antiviral activity of
chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob. Agents Chemother.
2009, 53, 3416–3421. [CrossRef]

Antioxidants 2020, 9, 894

11.

12.

13.
14.
15.

16.
17.

18.
19.

20.
21.
22.
23.

24.
25.

26.
27.
28.

29.
30.
31.
32.

14 of 19

Yao, X.; Ye, F.; Zhang, M.; Cui, C.; Huang, B.; Niu, P.; Liu, X.; Zhao, L.; Dong, E.; Song, C.; et al. In Vitro
Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. 2020. [CrossRef]
Vincent, M.J.; Bergeron, E.; Benjannet, S.; Erickson, B.R.; Rollin, P.E.; Ksiazek, T.G.; Seidah, N.G.; Nichol, S.T.
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J. 2005, 2, 69. [CrossRef]
[PubMed]
FDA. Available online: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19update-fda-revokes-emergency-use-authorization-chloroquine-and (accessed on 17 September 2020).
Canton, J.; Khezri, R.; Glogauer, M.; Grinstein, S. Contrasting phagosome pH regulation and maturation in
human M1 and M2 macrophages. Mol. Biol. Cell 2014, 25, 3330–3341. [CrossRef] [PubMed]
Ye, S.; Lowther, S.; Stambas, J. Inhibition of reactive oxygen species production ameliorates inflammation
induced by influenza A viruses via upregulation of SOCS1 and SOCS3. J. Virol. 2015, 89, 2672–2683.
[CrossRef] [PubMed]
Ye, Q.; Wang, B.; Mao, J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J. Infect.
2020, 80, 607–613. [CrossRef]
Herraiz, T.; Guillén, H.; González-Peña, D.; Arán, V.J. Antimalarial Quinoline Drugs Inhibit β-Hematin
and Increase Free Hemin Catalyzing Peroxidative Reactions and Inhibition of Cysteine Proteases. Sci. Rep.
2019, 9, 15398. [CrossRef]
Toler, S.M.; Noe, D.; Sharma, A. Selective enhancement of cellular oxidative stress by chloroquine: Implications
for the treatment of glioblastoma multiforme. Neurosurg. Focus 2006, 21, E10. [CrossRef]
Farombi, E.O.; Shyntum, Y.Y.; Emerole, G.O. Influence of chloroquine treatment and Plasmodium
falciparum malaria infection on some enzymatic and non-enzymatic antioxidant defense indices in humans.
Drug Chem. Toxicol. 2003, 26, 59–71. [CrossRef]
Farombi, E.O. Genotoxicity of chloroquine in rat liver cells: Protective role of free radical scavengers.
Cell Biol. Toxicol. 2006, 22, 159–167. [CrossRef]
Lehane, A.M.; McDevitt, C.A.; Kirk, K.; Fidock, D.A. Degrees of chloroquine resistance in Plasmodium—Is the
redox system involved? Int. J. Parasitol. Drugs Drug Resist. 2012, 2, 47–57. [CrossRef]
Camini, F.C.; da Silva Caetano, C.C.; Almeida, L.T.; de Brito Magalhães, C.L. Implications of oxidative stress
on viral pathogenesis. Arch. Virol. 2017, 162, 907–917. [CrossRef]
Wu, C.; Chen, X.; Cai, Y.; Xia, J.; Zhou, X.; Xu, S.; Huang, H.; Zhang, L.; Du, C.; Zhang, Y.; et al. Risk Factors
Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019
Pneumonia in Wuhan, China. JAMA Intern. Med. 2020. [CrossRef]
Chow, C.W.; Herrera Abreu, M.T.; Suzuki, T.; Downey, G.P. Oxidative stress and acute lung injury. Am. J.
Respir. Cell Mol. Biol. 2003, 29, 427–431. [CrossRef]
Rocksén, D.; Ekstrand-Hammarström, B.; Johansson, L.; Bucht, A. Vitamin E reduces transendothelial
migration of neutrophils and prevents lung injury in endotoxin-induced airway inflammation.
Am. J. Respir. Cell Mol. Biol. 2003, 28, 199–207. [CrossRef]
Stone, W.L.; Mukherjee, S.; Smith, M.; Das, S.K. Therapeutic uses of antioxidant liposomes. Methods Mol.
Biol. (Clifton N. J.) 2002, 199, 145–161. [CrossRef]
Stone, W.L.; Smith, M. Therapeutic uses of antioxidant liposomes. Mol. Biotechnol. 2004, 27, 217–230.
[CrossRef]
Al-Bari, M.A. Chloroquine analogues in drug discovery: New directions of uses, mechanisms of actions and
toxic manifestations from malaria to multifarious diseases. J. Antimicrob. Chemother. 2015, 70, 1608–1621.
[CrossRef]
Schrezenmeier, E.; Dörner, T. Mechanisms of action of hydroxychloroquine and chloroquine: Implications for
rheumatology. Nat. Rev. Rheumatol. 2020, 16, 155–166. [CrossRef]
Breiden, B.; Sandhoff, K. Emerging mechanisms of drug-induced phospholipidosis. Biol. Chem.
2019, 401, 31–46. [CrossRef]
Lüllmann, H.; Wehling, M. The binding of drugs to different polar lipids in vitro. Biochem. Pharmacol.
1979, 28, 3409–3415. [CrossRef]
Seydel, J.K.; Wassermann, O. NMR-studies on the molecular basis of drug-induced phospholipidosis–II.
Interaction between several amphiphilic drugs and phospholipids. Biochem. Pharmacol. 1976, 25, 2357–2364.
[CrossRef]

Antioxidants 2020, 9, 894

33.
34.
35.
36.
37.
38.
39.
40.

41.
42.
43.
44.

45.

46.
47.

48.

49.
50.
51.

52.
53.
54.
55.

15 of 19

Halliwell, W.H. Cationic amphiphilic drug-induced phospholipidosis. Toxicol. Pathol. 1997, 25, 53–60.
[CrossRef] [PubMed]
Forgac, M. Vacuolar ATPases: Rotary proton pumps in physiology and pathophysiology.
Nat. Rev. Mol. Cell Biol. 2007, 8, 917–929. [CrossRef] [PubMed]
Lu, S.; Sung, T.; Lin, N.; Abraham, R.T.; Jessen, B.A. Lysosomal adaptation: How cells respond to lysosomotropic
compounds. PLoS ONE 2017, 12, e0173771. [CrossRef]
Homewood, C.A.; Warhurst, D.C.; Peters, W.; Baggaley, V.C. Lysosomes, pH and the anti-malarial action of
chloroquine. Nature 1972, 235, 50–52. [CrossRef]
Ohkuma, S.; Poole, B. Fluorescence probe measurement of the intralysosomal pH in living cells and the
perturbation of pH by various agents. Proc. Natl. Acad. Sci. USA 1978, 75, 3327–3331. [CrossRef]
Daniel, W.A.; Bickel, M.H.; Honegger, U.E. The contribution of lysosomal trapping in the uptake of
desipramine and chloroquine by different tissues. Pharmacol. Toxicol. 1995, 77, 402–406. [CrossRef]
Ndiaye, N.; Petrognani, R.; Diatta, B.; Seck, M.; Theobald, X.; Adnet, P. Chloroquine poisoning with
respiratory distress and fatal outcome. Ann. Fr. Anesth. Reanim. 1999, 18, 683–685. [CrossRef]
Fois, G.; Hobi, N.; Felder, E.; Ziegler, A.; Miklavc, P.; Walther, P.; Radermacher, P.; Haller, T.; Dietl, P. A new
role for an old drug: Ambroxol triggers lysosomal exocytosis via pH-dependent Ca2+ release from acidic
Ca2+ stores. Cell Calcium 2015, 58, 628–637. [CrossRef]
Schmitz, G.; Müller, G. Structure and function of lamellar bodies, lipid-protein complexes involved in storage
and secretion of cellular lipids. J. Lipid Res. 1991, 32, 1539–1570.
Akella, A.; Deshpande, S.B. Pulmonary surfactants and their role in pathophysiology of lung disorders.
Indian J. Exp. Biol 2013, 51, 5–22. [PubMed]
Mason, R.J. Pathogenesis of COVID-19 from a cell biology perspective. Eur. Respir. J. 2020, 55. [CrossRef]
[PubMed]
Zhang, L.N.; Sun, J.P.; Xue, X.Y.; Wang, J.X. Exogenous pulmonary surfactant for acute respiratory distress
syndrome in adults: A systematic review and meta-analysis. Exp. Ther. Med. 2013, 5, 237–242. [CrossRef]
[PubMed]
Meng, S.S.; Chang, W.; Lu, Z.H.; Xie, J.F.; Qiu, H.B.; Yang, Y.; Guo, F.M. Effect of surfactant administration on
outcomes of adult patients in acute respiratory distress syndrome: A meta-analysis of randomized controlled
trials. BMC Pulm. Med. 2019, 19, 9. [CrossRef] [PubMed]
Beers, M.F. Inhibition of cellular processing of surfactant protein C by drugs affecting intracellular pH
gradients. J. Biol. Chem. 1996, 271, 14361–14370. [CrossRef]
Rodríguez-Capote, K.; Manzanares, D.; Haines, T.; Possmayer, F. Reactive oxygen species inactivation of
surfactant involves structural and functional alterations to surfactant proteins SP-B and SP-C. Biophys. J.
2006, 90, 2808–2821. [CrossRef]
Hamaguchi, R.; Haginaka, J.; Tanimoto, T.; Kuroda, Y. Maintenance of luminal pH and protease activity
in lysosomes/late endosomes by vacuolar ATPase in chlorpromazine-treated RAW264 cells accumulating
phospholipids. Cell Biol. Toxicol. 2014, 30, 67–77. [CrossRef]
Tietz, P.S.; Yamazaki, K.; LaRusso, N.F. Time-dependent effects of chloroquine on pH of hepatocyte lysosomes.
Biochem. Pharmacol. 1990, 40, 1419–1421. [CrossRef]
Shayman, J.A.; Abe, A. Drug induced phospholipidosis: An acquired lysosomal storage disorder. Biochim.
Biophys. Acta 2013, 1831, 602–611. [CrossRef]
Robison, R.L.; Visscher, G.E.; Roberts, S.A.; Engstrom, R.G.; Hartman, H.A.; Ballard, F.H. Generalized
phospholipidosis induced by an amphiphilic cationic psychotropic drug. Toxicol. Pathol. 1985, 13, 335–348.
[CrossRef]
Jankowski, A.; Scott, C.C.; Grinstein, S. Determinants of the phagosomal pH in neutrophils. J. Biol. Chem.
2002, 277, 6059–6066. [CrossRef] [PubMed]
Jankowski, A.; Grinstein, S. Modulation of the cytosolic and phagosomal pH by the NADPH oxidase.
Antioxid. Redox Signal. 2002, 4, 61–68. [CrossRef] [PubMed]
Nunes, P.; Demaurex, N.; Dinauer, M.C. Regulation of the NADPH oxidase and associated ion fluxes during
phagocytosis. Traffic 2013, 14, 1118–1131. [CrossRef]
Luzio, J.P.; Pryor, P.R.; Bright, N.A. Lysosomes: Fusion and function. Nat. Rev. Mol. Cell Biol. 2007, 8, 622–632.
[CrossRef]

Antioxidants 2020, 9, 894

56.

57.
58.

59.

60.
61.

62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.

74.

75.
76.
77.
78.
79.

16 of 19

Burkard, C.; Verheije, M.H.; Wicht, O.; van Kasteren, S.I.; van Kuppeveld, F.J.; Haagmans, B.L.; Pelkmans, L.;
Rottier, P.J.; Bosch, B.J.; de Haan, C.A. Coronavirus cell entry occurs through the endo-/lysosomal pathway
in a proteolysis-dependent manner. PLoS Pathog. 2014, 10, e1004502. [CrossRef]
Yang, N.; Shen, H.M. Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic
Strategy in COVID-19. Int. J. Biol. Sci. 2020, 16, 1724–1731. [CrossRef] [PubMed]
Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.;
Wu, N.H.; Nitsche, A.; et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a
Clinically Proven Protease Inhibitor. Cell 2020, 181, 271–280.e278. [CrossRef] [PubMed]
Inoue, Y.; Tanaka, N.; Tanaka, Y.; Inoue, S.; Morita, K.; Zhuang, M.; Hattori, T.; Sugamura, K.
Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing
ACE2 with the cytoplasmic tail deleted. J. Virol. 2007, 81, 8722–8729. [CrossRef]
Al-Bari, M.A.A. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the
treatment of emerging viral diseases. Pharmacol. Res. Perspect. 2017, 5, e00293. [CrossRef]
Singh, A.K.; Singh, A.; Shaikh, A.; Singh, R.; Misra, A. Chloroquine and hydroxychloroquine in the treatment
of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference
to India and other developing countries. Diabetes Metab. Syndr. 2020, 14, 241–246. [CrossRef]
Demine, S.; Renard, P.; Arnould, T. Mitochondrial Uncoupling: A Key Controller of Biological Processes in
Physiology and Diseases. Cells 2019, 8, 795. [CrossRef] [PubMed]
Tsujimoto, Y. Apoptosis and necrosis: Intracellular ATP level as a determinant for cell death modes.
Cell Death Differ. 1997, 4, 429–434. [CrossRef] [PubMed]
Kvansakul, M. Viral Infection and Apoptosis. Viruses 2017, 9, 356. [CrossRef] [PubMed]
Martinon, F. Signaling by ROS drives inflammasome activation. Eur. J. Immunol. 2010, 40, 616–619. [CrossRef]
[PubMed]
Collin, F. Chemical Basis of Reactive Oxygen Species Reactivity and Involvement in Neurodegenerative
Diseases. Int. J. Mol. Sci. 2019, 20, 2407. [CrossRef]
Stone, W.L.; Basit, H.; Mohiuddin, S.S. Biochemistry, Antioxidants. In StatPearls [Internet]; StatPearls Publishing:
Treasure Island, FL, USA, 2019.
Murphy, M.P. How mitochondria produce reactive oxygen species. Biochem. J. 2009, 417, 1–13. [CrossRef]
Onukwufor, J.O.; Berry, B.J.; Wojtovich, A.P. Physiologic Implications of Reactive Oxygen Species Production
by Mitochondrial Complex I Reverse Electron Transport. Antioxidants 2019, 8, 285. [CrossRef]
Hamanaka, R.B.; Chandel, N.S. Mitochondrial reactive oxygen species regulate cellular signaling and dictate
biological outcomes. Trends Biochem. Sci. 2010, 35, 505–513. [CrossRef]
Liu, T.; Zhang, L.; Joo, D.; Sun, S.C. NF-κB signaling in inflammation. Signal. Transduct. Target. Ther. 2017, 2.
[CrossRef]
Morgan, M.J.; Liu, Z.G. Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res. 2011, 21, 103–115.
[CrossRef]
Park, J.; Kwon, D.; Choi, C.; Oh, J.W.; Benveniste, E.N. Chloroquine induces activation of nuclear factor-kappaB
and subsequent expression of pro-inflammatory cytokines by human astroglial cells. J. Neurochem.
2003, 84, 1266–1274. [CrossRef] [PubMed]
Yang, S.; Qiang, L.; Sample, A.; Shah, P.; He, Y.Y. NF-κB Signaling Activation Induced by Chloroquine
Requires Autophagosome, p62 Protein, and c-Jun N-terminal Kinase (JNK) Signaling and Promotes Tumor
Cell Resistance. J. Biol. Chem. 2017, 292, 3379–3388. [CrossRef] [PubMed]
Murphy, M.P.; Smith, R.A. Targeting antioxidants to mitochondria by conjugation to lipophilic
cations. Annu. Rev. Pharmacol. Toxicol. 2007, 47, 629–656. [CrossRef] [PubMed]
Anderson, E.J.; Katunga, L.A.; Willis, M.S. Mitochondria as a source and target of lipid peroxidation products
in healthy and diseased heart. Clin. Exp. Pharmacol. Physiol. 2012, 39, 179–193. [CrossRef] [PubMed]
Wilkerson, R.G.; Adler, J.D.; Shah, N.G.; Brown, R. Silent hypoxia: A harbinger of clinical deterioration in
patients with COVID-19. Am. J. Emerg. Med. 2020. [CrossRef] [PubMed]
Ayala, A.; Muñoz, M.F.; Argüelles, S. Lipid peroxidation: Production, metabolism, and signaling mechanisms
of malondialdehyde and 4-hydroxy-2-nonenal. Oxidative Med. Cell Longev. 2014, 2014, 360438. [CrossRef]
Handy, D.E.; Lubos, E.; Yang, Y.; Galbraith, J.D.; Kelly, N.; Zhang, Y.Y.; Leopold, J.A.; Loscalzo, J. Glutathione
peroxidase-1 regulates mitochondrial function to modulate redox-dependent cellular responses. J. Biol. Chem.
2009, 284, 11913–11921. [CrossRef]

Antioxidants 2020, 9, 894

80.
81.
82.
83.
84.
85.

86.

87.
88.
89.
90.
91.
92.
93.

94.

95.

96.
97.
98.
99.

100.
101.
102.
103.

17 of 19

Deepalakshmi, P.D.; Parasakthy, K.; Shanthi, S.; Devaraj, N.S. Effect of chloroquine on rat liver mitochondria.
Indian J. Exp. Biol. 1994, 32, 797–799.
Katewa, S.D.; Katyare, S.S. Treatment with antimalarials adversely affects the oxidative energy metabolism
in rat liver mitochondria. Drug Chem. Toxicol. 2004, 27, 41–53. [CrossRef]
Berry, B.J.; Trewin, A.J.; Amitrano, A.M.; Kim, M.; Wojtovich, A.P. Use the Protonmotive Force: Mitochondrial
Uncoupling and Reactive Oxygen Species. J. Mol. Biol. 2018, 430, 3873–3891. [CrossRef]
Nainu, F.; Shiratsuchi, A.; Nakanishi, Y. Induction of Apoptosis and Subsequent Phagocytosis of Virus-Infected
Cells As an Antiviral Mechanism. Front. Immunol. 2017, 8, 1220. [CrossRef] [PubMed]
Mills, E.L.; Debets-Ossenkopp, Y.; Verbrugh, H.A.; Verhoef, J. Initiation of the respiratory burst of human
neutrophils by influenza virus. Infect. Immun. 1981, 32, 1200–1205. [CrossRef] [PubMed]
Coperchini, F.; Chiovato, L.; Croce, L.; Magri, F.; Rotondi, M. The cytokine storm in COVID-19: An overview
of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020, 53, 25–32.
[CrossRef] [PubMed]
Varga, Z.; Flammer, A.J.; Steiger, P.; Haberecker, M.; Andermatt, R.; Zinkernagel, A.S.; Mehra, M.R.;
Schuepbach, R.A.; Ruschitzka, F.; Moch, H. Endothelial cell infection and endotheliitis in COVID-19. Lancet
2020. [CrossRef]
Westlin, W.F.; Gimbrone, M.A. Neutrophil-mediated damage to human vascular endothelium. Role of
cytokine activation. Am. J. Pathol. 1993, 142, 117–128.
Szmitko, P.E.; Wang, C.H.; Weisel, R.D.; de Almeida, J.R.; Anderson, T.J.; Verma, S. New markers of
inflammation and endothelial cell activation: Part I. Circulation 2003, 108, 1917–1923. [CrossRef]
Winterbourn, C.C.; Kettle, A.J. Redox reactions and microbial killing in the neutrophil phagosome.
Antioxid. Redox Signal. 2013, 18, 642–660. [CrossRef]
Singel, K.L.; Segal, B.H. NOX2-dependent regulation of inflammation. Clin. Sci. 2016, 130, 479–490.
[CrossRef]
Zemans, R.L.; Matthay, M.A. What drives neutrophils to the alveoli in ARDS? Thorax 2017, 72, 1–3. [CrossRef]
Huang, X.; Xiu, H.; Zhang, S.; Zhang, G. The Role of Macrophages in the Pathogenesis of ALI/ARDS.
Med. Inflamm. 2018, 2018, 1264913. [CrossRef]
Minari, J.B.; Oloyede, O.B. Immunosupressive effect of chloroquine through the inhibition of
myeloperoxidase. In Proceedings of the 2nd International Conference on Clinical & Cellular Immunology,
Hampton Inn Tropicana, Las Vegas, NV, USA, 15–17 October 2013.
Labro, M.T.; Babin-Chevaye, C. Effects of amodiaquine, chloroquine, and mefloquine on human
polymorphonuclear neutrophil function in vitro. Antimicrob. Agents Chemother. 1988, 32, 1124–1130.
[CrossRef] [PubMed]
Chen, D.; Xie, J.; Fiskesund, R.; Dong, W.; Liang, X.; Lv, J.; Jin, X.; Liu, J.; Mo, S.; Zhang, T.; et al. Publisher
Correction: Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages
toward M1 phenotype. Nat. Commun. 2018, 9, 1808. [CrossRef] [PubMed]
Ley, K. M1 Means Kill; M2 Means Heal. J. Immunol. 2017, 199, 2191–2193. [CrossRef] [PubMed]
Kourtzelis, I.; Hajishengallis, G.; Chavakis, T. Phagocytosis of Apoptotic Cells in Resolution of Inflammation.
Front. Immunol. 2020, 11, 553. [CrossRef] [PubMed]
Delgado-Roche, L.; Mesta, F. Oxidative Stress as Key Player in Severe Acute Respiratory Syndrome
Coronavirus (SARS-CoV) Infection. Arch. Med. Res. 2020, 51, 384–387. [CrossRef]
Sugioka, Y.; Suzuki, M.; Sugioka, K.; Nakano, M. A ferriprotoporphyrin IX-chloroquine complex
promotes membrane phospholipid peroxidation. A possible mechanism for antimalarial action. FEBS Lett.
1987, 223, 251–254. [CrossRef]
Bhattacharyya, B.; Chatterjee, T.K.; Ghosh, J.J. Effects of chloroquine on lysosomal enzymes, NADPH-induced
lipid peroxidation, and antioxidant enzymes of rat retina. Biochem. Pharmacol. 1983, 32, 2965–2968. [CrossRef]
Yusuf, I.H.; Sharma, S.; Luqmani, R.; Downes, S.M. Hydroxychloroquine retinopathy. Eye 2017, 31, 828–845.
[CrossRef]
Ogunbayo, O.A.; Adisa, R.A.; Ademowo, O.G.; Olorunsogo, O. Incidence of Chloroquine Induced Oxidative
Stress in the Blood of Rabbit. Int. J. Pharmacol. 2006, 2, 121–125. [CrossRef]
Giovanella, F.; Ferreira, G.K.; de Prá, S.D.; Carvalho-Silva, M.; Gomes, L.M.; Scaini, G.; Gonçalves, R.C.;
Michels, M.; Galant, L.S.; Longaretti, L.M.; et al. Effects of primaquine and chloroquine on oxidative stress
parameters in rats. An. Acad. Bras. Cienc. 2015, 87, 1487–1496. [CrossRef]

Antioxidants 2020, 9, 894

18 of 19

104. Fang, L.; Neutzner, A.; Turtschi, S.; Flammer, J.; Mozaffarieh, M. Comet assay as an indirect measure of
systemic oxidative stress. J. Vis. Exp. 2015, e52763. [CrossRef] [PubMed]
105. Stone, W.L.; Farnsworth, C.C.; Dratz, E.A. A reinvestigation of the fatty acid content of bovine, rat and frog
retinal rod outer segments. Exp. Eye Res. 1979, 28, 387–397. [CrossRef]
106. Song, J.H.; Fujimoto, K.; Miyazawa, T. Polyunsaturated (n-3) Fatty Acids Susceptible to Peroxidation Are
Increased in Plasma and Tissue Lipids of Rats Fed Docosahexaenoic Acid–Containing Oils. J. Nutr. 2000, 130,
3028–3033. [CrossRef] [PubMed]
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